Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

intrathecal deferoxamine

An intrathecal (IT) formulation of deferoxamine (DFO), an iron-chelating agent that can be used to deplete free iron and lower iron levels, and with potential antineoplastic activity. Upon IT administration via Ommaya reservoir, DFO chelates free iron within the cerebrospinal fluid (CSF) by forming the iron complex ferrioxamine. This lowers the amount of iron available for cancer cell growth and survival. Cancer cells show increased iron uptake as iron is needed for rapid tumor cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	IT deferoxamine IT desferrioxamine
Abbreviation:	IT-DFO

intrathecal deferoxamine

Search NCI's Drug Dictionary